NO319022B1 - Tumorcytotoksisk-faktor-II-mutanter - Google Patents

Tumorcytotoksisk-faktor-II-mutanter Download PDF

Info

Publication number: NO319022B1
Authority: NO; Norway
Prior art keywords: tcf; mutant; cells; mutants; ala
Prior art date: 1994-12-27

Application number

NO19963552A

Other languages

English (en)

Norwegian (no)

Other versions

NO963552L (no

NO963552D0 (no

Inventor

Kanji Higashio

Kyoji Yamaguchi

Akihiko Murakami

Masaaki Goto

Masatsugu Ueda

Fumie Kobayashi

Masahiko Kinosaki

Yasushi Yamashita

Original Assignee

Daiichi Seiyaku Co

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1994-12-27

Filing date

1996-08-26

Publication date

2005-06-06

1996-08-26 Application filed by Daiichi Seiyaku Co filed Critical Daiichi Seiyaku Co

1996-08-26 Publication of NO963552D0 publication Critical patent/NO963552D0/no

1996-10-28 Publication of NO963552L publication Critical patent/NO963552L/no

2005-06-06 Publication of NO319022B1 publication Critical patent/NO319022B1/no

Links

108010094028 Prothrombin Proteins 0.000 title claims description 12
AGVAZMGAQJOSFJ-WZHZPDAFSA-M cobalt(2+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+2].N#[C-].[N-]([C@@H]1[C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP(O)(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O AGVAZMGAQJOSFJ-WZHZPDAFSA-M 0.000 title claims description 10
206010028980 Neoplasm Diseases 0.000 claims description 17
239000003145 cytotoxic factor Substances 0.000 claims description 5
108010084094 alanyl-alanyl-alanyl-alanine Proteins 0.000 claims description 2
231100000433 cytotoxic Toxicity 0.000 claims 6
230000001472 cytotoxic effect Effects 0.000 claims 6
108010074864 Factor XI Proteins 0.000 claims 1
210000004027 cell Anatomy 0.000 description 29
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 24
108090000623 proteins and genes Proteins 0.000 description 24
102000004169 proteins and genes Human genes 0.000 description 24
239000013612 plasmid Substances 0.000 description 21
238000003752 polymerase chain reaction Methods 0.000 description 21
230000004071 biological effect Effects 0.000 description 20
HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 18
230000000694 effects Effects 0.000 description 18
239000012634 fragment Substances 0.000 description 18
229960002897 heparin Drugs 0.000 description 18
229920000669 heparin Polymers 0.000 description 18
238000000034 method Methods 0.000 description 18
239000011541 reaction mixture Substances 0.000 description 18
239000002609 medium Substances 0.000 description 16
230000002062 proliferating effect Effects 0.000 description 16
239000013604 expression vector Substances 0.000 description 15
241000588724 Escherichia coli Species 0.000 description 14
125000003275 alpha amino acid group Chemical group 0.000 description 12
238000006243 chemical reaction Methods 0.000 description 12
HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 12
108091008146 restriction endonucleases Proteins 0.000 description 12
239000011780 sodium chloride Substances 0.000 description 12
239000000243 solution Substances 0.000 description 12
239000002299 complementary DNA Substances 0.000 description 11
239000013613 expression plasmid Substances 0.000 description 11
108020004414 DNA Proteins 0.000 description 10
229960000723 ampicillin Drugs 0.000 description 10
AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 10
210000002966 serum Anatomy 0.000 description 10
210000003494 hepatocyte Anatomy 0.000 description 9
241000620209 Escherichia coli DH5[alpha] Species 0.000 description 8
229920001213 Polysorbate 20 Polymers 0.000 description 8
239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 8
235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 8
108091028043 Nucleic acid sequence Proteins 0.000 description 7
238000010276 construction Methods 0.000 description 7
238000001727 in vivo Methods 0.000 description 7
QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 6
238000001712 DNA sequencing Methods 0.000 description 6
229920002684 Sepharose Polymers 0.000 description 6
150000001413 amino acids Chemical class 0.000 description 6
210000004978 chinese hamster ovary cell Anatomy 0.000 description 6
235000012000 cholesterol Nutrition 0.000 description 6
239000000203 mixture Substances 0.000 description 6
238000002703 mutagenesis Methods 0.000 description 6
231100000350 mutagenesis Toxicity 0.000 description 6
108091003079 Bovine Serum Albumin Proteins 0.000 description 5
210000002798 bone marrow cell Anatomy 0.000 description 5
238000005119 centrifugation Methods 0.000 description 5
230000014509 gene expression Effects 0.000 description 5
238000004519 manufacturing process Methods 0.000 description 5
239000006228 supernatant Substances 0.000 description 5
239000006144 Dulbecco’s modiﬁed Eagle's medium Substances 0.000 description 4
238000010828 elution Methods 0.000 description 4
239000012894 fetal calf serum Substances 0.000 description 4
230000035772 mutation Effects 0.000 description 4
238000002360 preparation method Methods 0.000 description 4
AVWQQPYHYQKEIZ-UHFFFAOYSA-K trisodium;2-dodecylbenzenesulfonate;3-dodecylbenzenesulfonate;4-dodecylbenzenesulfonate Chemical compound [Na+].[Na+].[Na+].CCCCCCCCCCCCC1=CC=C(S([O-])(=O)=O)C=C1.CCCCCCCCCCCCC1=CC=CC(S([O-])(=O)=O)=C1.CCCCCCCCCCCCC1=CC=CC=C1S([O-])(=O)=O AVWQQPYHYQKEIZ-UHFFFAOYSA-K 0.000 description 4
UZOVYGYOLBIAJR-UHFFFAOYSA-N 4-isocyanato-4'-methyldiphenylmethane Chemical compound C1=CC(C)=CC=C1CC1=CC=C(N=C=O)C=C1 UZOVYGYOLBIAJR-UHFFFAOYSA-N 0.000 description 3
102220476198 Gamma-secretase subunit PEN-2_K54A_mutation Human genes 0.000 description 3
108010023302 HDL Cholesterol Proteins 0.000 description 3
102100021866 Hepatocyte growth factor Human genes 0.000 description 3
102220479548 Interleukin-10_R42A_mutation Human genes 0.000 description 3
241000700159 Rattus Species 0.000 description 3
102000004142 Trypsin Human genes 0.000 description 3
108090000631 Trypsin Proteins 0.000 description 3
238000002835 absorbance Methods 0.000 description 3
239000002246 antineoplastic agent Substances 0.000 description 3
230000009286 beneficial effect Effects 0.000 description 3
239000007795 chemical reaction product Substances 0.000 description 3
238000001962 electrophoresis Methods 0.000 description 3
210000002919 epithelial cell Anatomy 0.000 description 3
239000006167 equilibration buffer Substances 0.000 description 3
238000001914 filtration Methods 0.000 description 3
239000000047 product Substances 0.000 description 3
238000000746 purification Methods 0.000 description 3
150000003839 salts Chemical class 0.000 description 3
239000012588 trypsin Substances 0.000 description 3
108010088751 Albumins Proteins 0.000 description 2
102000009027 Albumins Human genes 0.000 description 2
NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
230000006820 DNA synthesis Effects 0.000 description 2
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
108010049003 Fibrinogen Proteins 0.000 description 2
102000008946 Fibrinogen Human genes 0.000 description 2
108010010234 HDL Lipoproteins Proteins 0.000 description 2
108090000100 Hepatocyte Growth Factor Proteins 0.000 description 2
102000008133 Iron-Binding Proteins Human genes 0.000 description 2
108010035210 Iron-Binding Proteins Proteins 0.000 description 2
102100027378 Prothrombin Human genes 0.000 description 2
239000004098 Tetracycline Substances 0.000 description 2
238000004458 analytical method Methods 0.000 description 2
230000000259 anti-tumor effect Effects 0.000 description 2
238000010367 cloning Methods 0.000 description 2
238000005516 engineering process Methods 0.000 description 2
229940012952 fibrinogen Drugs 0.000 description 2
239000011521 glass Substances 0.000 description 2
239000003102 growth factor Substances 0.000 description 2
239000001963 growth medium Substances 0.000 description 2
238000000338 in vitro Methods 0.000 description 2
238000011835 investigation Methods 0.000 description 2
150000002505 iron Chemical class 0.000 description 2
210000001985 kidney epithelial cell Anatomy 0.000 description 2
208000019423 liver disease Diseases 0.000 description 2
239000011159 matrix material Substances 0.000 description 2
239000002773 nucleotide Substances 0.000 description 2
125000003729 nucleotide group Chemical group 0.000 description 2
239000008363 phosphate buffer Substances 0.000 description 2
150000003904 phospholipids Chemical class 0.000 description 2
239000002244 precipitate Substances 0.000 description 2
235000012434 pretzels Nutrition 0.000 description 2
229940039716 prothrombin Drugs 0.000 description 2
239000012264 purified product Substances 0.000 description 2
238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 2
239000000725 suspension Substances 0.000 description 2
229960002180 tetracycline Drugs 0.000 description 2
229940104230 thymidine Drugs 0.000 description 2
230000009466 transformation Effects 0.000 description 2
238000005406 washing Methods 0.000 description 2
PGOHTUIFYSHAQG-LJSDBVFPSA-N (2S)-6-amino-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-1-[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-1-[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-4-methylsulfanylbutanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-5-carbamimidamidopentanoyl]amino]propanoyl]pyrrolidine-2-carbonyl]amino]-3-methylbutanoyl]amino]-4-methylpentanoyl]amino]-4-methylpentanoyl]amino]acetyl]amino]-3-hydroxypropanoyl]amino]-4-methylpentanoyl]amino]-3-sulfanylpropanoyl]amino]-4-methylsulfanylbutanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-hydroxybutanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-hydroxypropanoyl]amino]-3-hydroxypropanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]-4-methylpentanoyl]amino]-3-hydroxybutanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-5-carbamimidamidopentanoyl]amino]-5-oxopentanoyl]amino]-3-hydroxybutanoyl]amino]-3-hydroxypropanoyl]amino]-3-carboxypropanoyl]amino]-3-hydroxypropanoyl]amino]-5-oxopentanoyl]amino]-5-oxopentanoyl]amino]-3-phenylpropanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-methylbutanoyl]amino]-4-methylpentanoyl]amino]-4-oxobutanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-4-carboxybutanoyl]amino]-5-oxopentanoyl]amino]hexanoic acid Chemical compound CSCC[C@H](N)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCCN)C(O)=O PGOHTUIFYSHAQG-LJSDBVFPSA-N 0.000 description 1
BZSALXKCVOJCJJ-IPEMHBBOSA-N (4s)-4-[[(2s)-2-acetamido-3-methylbutanoyl]amino]-5-[[(2s)-1-[[(2s)-1-[[(2s,3r)-1-[[(2s)-1-[[(2s)-1-[[2-[[(2s)-1-amino-1-oxo-3-phenylpropan-2-yl]amino]-2-oxoethyl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-1-oxopropan-2-yl]amino]-3-hydroxy Chemical compound CC(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCC)C(=O)N[C@@H](CCCC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(=O)N[C@H](C(N)=O)CC1=CC=CC=C1 BZSALXKCVOJCJJ-IPEMHBBOSA-N 0.000 description 1
FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
-1 Ala Chemical class 0.000 description 1
102100027211 Albumin Human genes 0.000 description 1
206010002091 Anaesthesia Diseases 0.000 description 1
101000972324 Cynodon dactylon Leaf protein Proteins 0.000 description 1
241000701022 Cytomegalovirus Species 0.000 description 1
241000289427 Didelphidae Species 0.000 description 1
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
108090000790 Enzymes Proteins 0.000 description 1
102000004190 Enzymes Human genes 0.000 description 1
241001288713 Escherichia coli MC1061 Species 0.000 description 1
238000012752 Hepatectomy Methods 0.000 description 1
102100022123 Hepatocyte nuclear factor 1-beta Human genes 0.000 description 1
101000898034 Homo sapiens Hepatocyte growth factor Proteins 0.000 description 1
101001045758 Homo sapiens Hepatocyte nuclear factor 1-beta Proteins 0.000 description 1
241001262617 Japonica Species 0.000 description 1
101500021084 Locusta migratoria 5 kDa peptide Proteins 0.000 description 1
241001465754 Metazoa Species 0.000 description 1
108700010674 N-acetylVal-Nle(7,8)- allatotropin (5-13) Proteins 0.000 description 1
108091034117 Oligonucleotide Proteins 0.000 description 1
239000012979 RPMI medium Substances 0.000 description 1
241000700157 Rattus norvegicus Species 0.000 description 1
108010000499 Thromboplastin Proteins 0.000 description 1
102000002262 Thromboplastin Human genes 0.000 description 1
JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
238000010521 absorption reaction Methods 0.000 description 1
125000000539 amino acid group Chemical group 0.000 description 1
235000019270 ammonium chloride Nutrition 0.000 description 1
230000037005 anaesthesia Effects 0.000 description 1
210000004102 animal cell Anatomy 0.000 description 1
239000000427 antigen Substances 0.000 description 1
102000036639 antigens Human genes 0.000 description 1
108091007433 antigens Proteins 0.000 description 1
238000003556 assay Methods 0.000 description 1
239000007640 basal medium Substances 0.000 description 1
229930189065 blasticidin Natural products 0.000 description 1
210000004369 blood Anatomy 0.000 description 1
239000008280 blood Substances 0.000 description 1
230000023555 blood coagulation Effects 0.000 description 1
238000010241 blood sampling Methods 0.000 description 1
230000037396 body weight Effects 0.000 description 1
229940098773 bovine serum albumin Drugs 0.000 description 1
239000007853 buffer solution Substances 0.000 description 1
229910052792 caesium Inorganic materials 0.000 description 1
TVFDJXOCXUVLDH-UHFFFAOYSA-N caesium atom Chemical compound [Cs] TVFDJXOCXUVLDH-UHFFFAOYSA-N 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
238000003776 cleavage reaction Methods 0.000 description 1
238000004440 column chromatography Methods 0.000 description 1
239000012228 culture supernatant Substances 0.000 description 1
238000012258 culturing Methods 0.000 description 1
238000012217 deletion Methods 0.000 description 1
230000037430 deletion Effects 0.000 description 1
238000000432 density-gradient centrifugation Methods 0.000 description 1
UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
229960003957 dexamethasone Drugs 0.000 description 1
201000010099 disease Diseases 0.000 description 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
210000003527 eukaryotic cell Anatomy 0.000 description 1
210000002950 fibroblast Anatomy 0.000 description 1
238000003018 immunoassay Methods 0.000 description 1
210000004185 liver Anatomy 0.000 description 1
210000004962 mammalian cell Anatomy 0.000 description 1
238000010369 molecular cloning Methods 0.000 description 1
230000003287 optical effect Effects 0.000 description 1
239000008188 pellet Substances 0.000 description 1
230000036470 plasma concentration Effects 0.000 description 1
230000002035 prolonged effect Effects 0.000 description 1
230000008929 regeneration Effects 0.000 description 1
238000011069 regeneration method Methods 0.000 description 1
230000007017 scission Effects 0.000 description 1
239000013049 sediment Substances 0.000 description 1
239000001509 sodium citrate Substances 0.000 description 1
NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
238000007619 statistical method Methods 0.000 description 1
239000000126 substance Substances 0.000 description 1
FRGKKTITADJNOE-UHFFFAOYSA-N sulfanyloxyethane Chemical compound CCOS FRGKKTITADJNOE-UHFFFAOYSA-N 0.000 description 1
229930101283 tetracycline Natural products 0.000 description 1
235000019364 tetracycline Nutrition 0.000 description 1
150000003522 tetracyclines Chemical class 0.000 description 1
238000001890 transfection Methods 0.000 description 1
210000004881 tumor cell Anatomy 0.000 description 1
239000013598 vector Substances 0.000 description 1
DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/4753—Hepatocyte growth factor; Scatter factor; Tumor cytotoxic factor II
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
- C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
Zoology (AREA)
Gastroenterology & Hepatology (AREA)
Molecular Biology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
General Health & Medical Sciences (AREA)
Biochemistry (AREA)
Genetics & Genomics (AREA)
Medicinal Chemistry (AREA)
Biophysics (AREA)
Toxicology (AREA)
Engineering & Computer Science (AREA)
Wood Science & Technology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Microbiology (AREA)
General Chemical & Material Sciences (AREA)
Biotechnology (AREA)
Peptides Or Proteins (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Saccharide Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)

NO19963552A 1994-12-27 1996-08-26 Tumorcytotoksisk-faktor-II-mutanter NO319022B1 (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
JP33788594		1994-12-27
PCT/JP1995/002708 WO1996020214A1 (fr)	1994-12-27	1995-12-27	Mutant de tcf

Publications (3)

Publication Number	Publication Date
NO963552D0 NO963552D0 (no)	1996-08-26
NO963552L NO963552L (no)	1996-10-28
NO319022B1 true NO319022B1 (no)	2005-06-06

Family

ID=18312917

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO19963552A NO319022B1 (no)	1994-12-27	1996-08-26	Tumorcytotoksisk-faktor-II-mutanter

Country Status (16)

Country	Link
US (2)	US6399744B1 (fr)
EP (2)	EP0757994B1 (fr)
JP (1)	JP3699482B2 (fr)
KR (1)	KR100294328B1 (fr)
AT (1)	ATE248913T1 (fr)
AU (1)	AU698221B2 (fr)
CA (1)	CA2183856C (fr)
DE (1)	DE69531673T2 (fr)
DK (1)	DK0757994T3 (fr)
ES (1)	ES2206523T3 (fr)
FI (1)	FI116223B (fr)
HU (1)	HU220167B (fr)
NO (1)	NO319022B1 (fr)
NZ (1)	NZ298142A (fr)
WO (1)	WO1996020214A1 (fr)
ZA (1)	ZA9510982B (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE69531673T2 (de) *	1994-12-27	2004-07-08	Daiichi Pharmaceutical Co., Ltd.	Tcf mutante
JP4006058B2 (ja)	1997-03-11	2007-11-14	第一三共株式会社	多臓器不全予防及び／又は治療剤
ES2274567T3 (es)	1997-03-14	2007-05-16	Daiichi Pharmaceutical Co., Ltd.	Utilizacion de tcf-ii para el tratamiento de la perdida de peso corporal, la anemia y la elevacion de tnf causadas por el cancer.
JP3961064B2 (ja) *	1997-03-28	2007-08-15	第一製薬株式会社	腎疾患予防及び／又は治療剤
KR100552434B1 (ko) *	1997-03-28	2006-05-16	다이이치세이야꾸 가부시끼가이샤	신질환 예방 및/또는 치료제_
GB9709453D0 (en) *	1997-05-10	1997-07-02	Imp Cancer Res Tech	Polypedtides and their use in therapy
DE19909251A1 (de)	1998-02-21	1999-08-26	Max Delbrueck Centrum	Mittel zur Therapie von menschlichen Erkrankungen, ausgehend von beta-Catenin, seine Herstellung und seine Verwendung

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
NZ232813A (en) *	1989-03-10	1992-08-26	Snow Brand Milk Products Co Ltd	Human fibroblast glycoprotein, cell differentiation, blood vessel endothelial cell growth factor, cellular immunology inforcing factor of 78 or 74 thousand daltons plus or minus two thousand daltons
ATE178354T1 (de) *	1990-07-13	1999-04-15	Snow Brand Milk Products Co Ltd	Plasmid das für die aminosäuresequenz von tcf-ii kodierende dns enthalt, transformierte zelle und produktion einer physiologisch aktiven substanz mit ihrer verwendung
WO1993023541A1 (fr) *	1992-05-18	1993-11-25	Genentech, Inc.	Variantes du facteur de croissance des hepatocytes
AU674871B2 (en) *	1992-07-16	1997-01-16	Atlas Pharmaceuticals Inc.	Blood coagulation normalizer containing TCF-II as active ingredient
WO1994014845A1 (fr) *	1992-12-28	1994-07-07	Snow Brand Milk Products Co., Ltd.	Facteur cytotoxique tumoral modifie
DE69531673T2 (de) *	1994-12-27	2004-07-08	Daiichi Pharmaceutical Co., Ltd.	Tcf mutante
JP3961064B2 (ja) *	1997-03-28	2007-08-15	第一製薬株式会社	腎疾患予防及び／又は治療剤
JPH1129493A (ja) *	1997-07-14	1999-02-02	Snow Brand Milk Prod Co Ltd	放射線障害予防及び／又は治療剤

1995
- 1995-12-27 DE DE69531673T patent/DE69531673T2/de not_active Expired - Fee Related
- 1995-12-27 JP JP52036596A patent/JP3699482B2/ja not_active Expired - Lifetime
- 1995-12-27 WO PCT/JP1995/002708 patent/WO1996020214A1/fr not_active Ceased
- 1995-12-27 AT AT95942271T patent/ATE248913T1/de not_active IP Right Cessation
- 1995-12-27 NZ NZ298142A patent/NZ298142A/xx not_active IP Right Cessation
- 1995-12-27 EP EP95942271A patent/EP0757994B1/fr not_active Expired - Lifetime
- 1995-12-27 DK DK95942271T patent/DK0757994T3/da active
- 1995-12-27 ZA ZA9510982A patent/ZA9510982B/xx unknown
- 1995-12-27 HU HU9602174A patent/HU220167B/hu not_active IP Right Cessation
- 1995-12-27 US US08/700,519 patent/US6399744B1/en not_active Expired - Fee Related
- 1995-12-27 ES ES95942271T patent/ES2206523T3/es not_active Expired - Lifetime
- 1995-12-27 AU AU43551/96A patent/AU698221B2/en not_active Ceased
- 1995-12-27 KR KR1019960704673A patent/KR100294328B1/ko not_active Expired - Fee Related
- 1995-12-27 CA CA002183856A patent/CA2183856C/fr not_active Expired - Fee Related
- 1995-12-27 EP EP02077639A patent/EP1275718A3/fr not_active Withdrawn
1996
- 1996-08-26 FI FI963313A patent/FI116223B/fi active IP Right Grant
- 1996-08-26 NO NO19963552A patent/NO319022B1/no not_active IP Right Cessation
2002
- 2002-04-25 US US10/133,912 patent/US20020165358A1/en not_active Abandoned

Also Published As

Publication number	Publication date
AU698221B2 (en)	1998-10-29
NO963552L (no)	1996-10-28
US6399744B1 (en)	2002-06-04
HU220167B (hu)	2001-11-28
ZA9510982B (en)	1996-08-22
FI116223B (fi)	2005-10-14
EP1275718A2 (fr)	2003-01-15
US20020165358A1 (en)	2002-11-07
DK0757994T3 (da)	2004-01-19
KR100294328B1 (ko)	2001-09-17
KR970701206A (ko)	1997-03-17
ATE248913T1 (de)	2003-09-15
WO1996020214A1 (fr)	1996-07-04
NO963552D0 (no)	1996-08-26
FI963313A0 (fi)	1996-08-26
EP0757994A1 (fr)	1997-02-12
CA2183856C (fr)	2006-11-07
HUT75236A (en)	1997-04-28
EP0757994A4 (fr)	1998-10-21
CA2183856A1 (fr)	1996-06-28
HU9602174D0 (en)	1996-10-28
AU4355196A (en)	1996-07-19
JP3699482B2 (ja)	2005-09-28
NZ298142A (en)	1997-08-22
EP1275718A3 (fr)	2003-03-19
FI963313L (fi)	1996-08-26
DE69531673D1 (de)	2003-10-09
EP0757994B1 (fr)	2003-09-03
ES2206523T3 (es)	2004-05-16
DE69531673T2 (de)	2004-07-08

Legal Events

Date	Code	Title	Description
2010-07-19	MM1K	Lapsed by not paying the annual fees

Publication	Publication Date	Title
JP2718426B2 (ja)	1998-02-25	糖鎖を持たないタンパク質を有効成分とする白血球増加剤
FI104903B (fi)	2000-04-28	Menetelmä kädellis-IL-3-proteiinin tuottamiseksi ja proteiinia koodaava rekombinantti-DNA-sekvenssi
WO1995021919A2 (fr)	1995-08-17	Proteine a activite de thrombopoietine (tpo)
JPWO1997019172A1 (ja)	1998-12-22	分化抑制ポリペプチド
NO323104B1 (no)	2007-01-02	Analoger av humant erytropoietin, DNA-sekvenser som koder for disse, eukaryot vertscelle transfektert med DNA-sekvensene, preparat som omfatter analogene, anvendelse av analogene til okning av hematokritt, og fremgangsmate for fremstilling av analogene.
JPH04505705A (ja)	1992-10-08	血管内皮細胞成長因子の生産およびそれをコードするｄｎａ
EP0941321A1 (fr)	1999-09-15	Polypeptides permutes de maniere circulaire et utilises en qualite de nouveaux agonistes du recepteur de facteur de cellule souche
WO1995028907A2 (fr)	1995-11-02	La megapoietine: nouveau facteur favorisant la croissance des megakaryocytes
JPH04506342A (ja)	1992-11-05	非グリコシル化ヒトインターロイキン―３類似蛋白質
JP2001514851A (ja)	2001-09-18	有利なグリコシル化プロフィルを有する組換えヒトエリスロポエチン
Graddis et al.	1998	Structure-function analysis of FLT3 ligand-FLT3 receptor interactions using a rapid functional screen
CA2648350A1 (fr)	1992-03-05	Analogues superieurs de la thrombomoduline a usage pharmaceutique
JPH11510062A (ja)	1999-09-07	多機能性造血受容体アゴニスト
NZ225411A (en)	1991-04-26	Hgm-csf human granulocyte macrophage colony stimulating factor and vector for its expression containing the sr#a# promoter of the plasmid deposited in atcc67318
EP0757994B1 (fr)	2003-09-03	Mutant de tcf
CA2050584A1 (fr)	1990-10-04	Activite de promotion de la croissance des megakaryocytes
JP2706704B2 (ja)	1998-01-28	組換ヒト肝実質細胞増殖因子
JPWO1996020214A1 (ja)	1997-03-25	Ｔｃｆ変異体
JPH05103675A (ja)	1993-04-27	ヒト神経成長因子２の製造法
KR100272867B1 (ko)	2000-11-15	Tpo활성을 갖는 단백질
EP0648268A1 (fr)	1995-04-19	Fragments therapeutiques du facteur willebrand
RU2233881C2 (ru)	2004-08-10	Средства и способ получения гемопоэтического белка
JP3292873B2 (ja)	2002-06-17	組換肝実質細胞増殖因子
AU775308B2 (en)	2004-07-29	Therapeutic compositions and methods for treating disease states with myeloid progenitor inhibitory factor-1 (MPIF-1), monocyte colony inhibitory factor (M-CIF), and macrophage inhibitory factor-4 (MIP-4)
JP2816971B2 (ja)	1998-10-27	組換肝実質細胞増殖因子